> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# UCB’s Bepranemab Misses Primary Endpoint
- URL: https://www.fdaweb.com/ucbs-bepranemab-misses-primary-endpoint/
- Published: 2024-10-31T12:00:00.000Z
- Updated: 2026-09-14T14:45:47.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5158102

UCB says its investigational Alzheimer’s drug bepranemab failed to meet its primary endpoint in the full population in the Phase 2a TOGETHER study, but slowed cognitive decline and the rate of tau accumulation in key secondary endpoints. The company [says](https://www.ucb.com/stories-media/Press-Releases/article/UCB-Presents-Encouraging-Data-on-Bepranemab-in-Early-Alzheimer-s-Disease-in-Phase-2a-Study-at-CTAD-2024?ref=fdaweb.com) the study is investigating the safety, efficacy, and tolerability of the drug, an anti-tau antibody targeting the mid-region of the tau protein in people living with prodromal to mild Alzheimer’s disease.

The company statement says the trial results “provide the first evidence of biological or clinical effect of a mid-domain tau-targeting disease-modifying therapy.” In pre-defined patient subgroups, it says, consistent treatment benefit was shown across multiple primary and secondary outcome measures, including cognition and function.

UCB chief scientific officer **Alistair Henry** says the company is “deeply encouraged by the proof of concept data for bepranemab, which highlight its potential to impact early Alzheimer’s disease progression. This strengthens our belief in the value of targeting the mid-region of tau as an important strategy in altering the trajectory of the disease.”

The firm says it is evaluating the next steps in its bepranemab development program.

The company describes bepranemab as a monoclonal antibody that specifically targets a mid-region epitope of human tau. In pathological conditions, it says, the mid-region of tau is thought to be essential for tau aggregation and is a key driver of neurodegeneration in Alzheimer’s disease.